Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Glioblastoma Multiforme
Efficacy of temsirolimus in recurrent glioblastoma multiforme evaluated
September 14th, 2005
The efficacy of temsirolimus in recurrent glioblastoma multiforme was evaluated. According to recent research from the United States, "Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiform (GBM). Recurrent GBM patients with {{<=}}1 chemotherapy regimen for progressive disease were eligible." "Temsirolimus was administered in a 250-mg intravenous dose weekly. Sixty-five patients were treated. The incidence of grade 3 or higher nonhematologic toxicity was 51%, and consisted mostly of hypercholesterolemia (11%), hypertriglyceridemia...
Source: Vaccine Weekly (2005-09-14)
|
